adalimumab beta

Adalimumab beta is an International Nonproprietary Name variant for an adalimumab biosimilar substance and refers to a recombinant human IgG1 monoclonal antibody that binds tumor necrosis factor alpha and prevents TNF-mediated inflammatory signaling. Like reference adalimumab, it is used in the broader anti-TNF therapeutic context for immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, and related disorders, although the exact commercial product, sponsor, formulation, and regulatory status cannot be assigned from the name alone. The molecule functions as a TNF blocker and may also lyse cells expressing membrane TNF in the presence of complement; however, the queried name appears to denote a biosimilar naming variant rather than a uniquely identifiable marketed product.

Other names

adalimumab beta